ml 23 has been researched along with Parkinsonian Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robertson, AD; Willis, GL | 2 |
| Willis, GL | 1 |
1 trial(s) available for ml 23 and Parkinsonian Disorders
| Article | Year |
|---|---|
Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
Topics: 5-Methoxytryptamine; Animals; Behavior, Animal; Callithrix; Cross-Over Studies; Eating; Male; Melatonin; Parkinsonian Disorders; Reaction Time; Recovery of Function | 2005 |
2 other study(ies) available for ml 23 and Parkinsonian Disorders
| Article | Year |
|---|---|
Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor.
Topics: 5-Methoxytryptamine; Animals; Male; Melatonin; Naphthalenes; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Melatonin; Recovery of Function | 2004 |
Intraocular microinjections repair experimental Parkinson's disease.
Topics: 5-Methoxytryptamine; Animals; Antiparkinson Agents; Circadian Rhythm; Levodopa; Male; Microinjections; Motor Activity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Retina | 2008 |